Serina Therapeutics advances POZ-VMAT2i into development for tardive dyskinesia: Huntsville, Alabama Thursday, July 31, 2025, 14:00 Hrs [IST] Serina Therapeutics, Inc. (Serina), a ...

Insightec, the Miami-based innovator in focused ultrasound to transform patient care, announced July 8 the U.S. Food and Drug ...

A team led by UT Southwestern Medical Center researchers has uncovered the atomic structure of a protein complex pivotal to ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a ...

Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

Analysts have set 12-month price targets for Neurocrine Biosciences, revealing an average target of $155.06, a high estimate of $182.00, and a low estimate of $115.00. This current average reflects an ...

Key Points Non-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. GAAP revenue reached $687.5 million for Q2 2025, beating expectations by $33.6 million and ...

Generic drugs had a "stable" performance in the second quarter, with global revenue down about 2% in local currency.

Adults with pediatric-onset bronchiectasis have increased disease severity compared with those with adult-onset bronchiectasis.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric ...